Romosozumab, clinical trials, and real-world care of patients with osteoporosis
Author(s) -
E. Michael Lewiecki
Publication year - 2020
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2020.03.196
Subject(s) - medicine , osteoporosis , clinical trial
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA Correspondence to: E. Michael Lewiecki, MD. New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA. Email mlewiecki@gmail.com. Provenance: This is an invited article commissioned by the Academic Editor Dr. Yusheng Li (Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China). Comment on: McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res 2018;33:1397-406.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom